Subcutaneous Treprostinil
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 86 | 肺動脈性肺高血圧症 | 9 |
86. 肺動脈性肺高血圧症
臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193
Showing 1 to 9 of 9 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02882126 (ClinicalTrials.gov) | June 201720170600 | 24/8/201620160824 | An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® ... | An Open-Label Extension Trial to Evaluate the Safety of Continued Therapy With Subcutaneous Remodulin® in Subjects With Pulmonary Arterial Hypertension Who Completed Study CVT-CV-003 An Open-Label Extension Trial to Evaluate the Safety of Continued Therapy With SubcutaneousRemodulin ... | Pulmonary Arterial Hypertension | Drug: Subcutaneous Treprostinil | United Therapeutics | CVie Therapeutics Co. Ltd. | Withdrawn | 18 Years | N/A | All | 0 | Phase 4 | China |
| 2 | NCT02893995 (ClinicalTrials.gov) | February 201720170200 | 24/8/201620160824 | Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® ... | A 16-Week, Open-Label, Multi-Center, Parallel, Randomized Controlled Study to Compare the Safety, Tolerability, Pharmacokinetics and Efficacy of Slow and Rapid Dose Titration Regimens of Subcutaneous Remodulin Therapy in Subjects With Pulmonary Arterial Hypertension A 16-Week, Open-Label, Multi-Center, Parallel, Randomized Controlled Study to Compare the Safety, To ... | Pulmonary Arterial Hypertension | Drug: Slow Dose Titration Group of Subcutaneous Treprostinil;Drug: Rapid Dose Titration Group of Subcutaneous Treprostinil Drug: Slow Dose Titration Group of Subcutaneous Treprostinil;Drug: Rapid Dose Titration Group of Sub ... | United Therapeutics | CVie Therapeutics Co. Ltd. | Withdrawn | 18 Years | N/A | All | 0 | Phase 4 | China |
| 3 | NCT01615627 (ClinicalTrials.gov) | July 1, 201220120701 | 6/6/201220120606 | Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain | Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain | Pulmonary Arterial Hypertension | Drug: HypotonicTreprostinil Solution;Drug: Eutonic Treprostinil Solution | Jewish General Hospital | NULL | Withdrawn | 18 Years | N/A | All | 0 | Phase 4 | Canada |
| 4 | EUCTR2011-004631-31-DE (EUCTR) | 13/03/201220120313 | 10/02/201220120210 | 16 week study is to assess the safety, tolerability and the effects on the body of a rapid dosing regimen using subcutaneous Remodulin® 16 week study is to assess the safety, tolerability and the effects on the body of a rapid dosing re ... | A 16 Week, Open Label, Multi-Centre, Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of a Rapid Dose Titration Regimen of Subcutaneous Remodulin® Therapy in Subjects with Pulmonary Arterial Hypertension - RAPID study A 16 Week, Open Label, Multi-Centre, Study to Evaluate the Safety, Tolerability and Pharmacodynamic ... | Pulmonary Arterial Hypertension (PAH) MedDRA version: 14.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 14.1;Level: LLT;Classification code 10065151;Term: Idiopathic pulmonary arterial hypertension;Classification code 10065152;Term: Familial pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Pulmonary Arterial Hypertension (PAH) MedDRA version: 14.1;Level: PT;Classification code 10064911;Te ... | Trade Name: Remodulin® (treprostinil) 1 mg/ml solution for infusion INN or Proposed INN: Treprostinil Other descriptive name: TREPROSTINIL SODIUM, UT-15 Trade Name: Remodulin® (treprostinil) 2.5 mg/ml solution for infusion INN or Proposed INN: Treprostinil Other descriptive name: TREPROSTINIL SODIUM, UT-15 Trade Name: Remodulin® (treprostinil) 5 mg/ml solution for infusion INN or Proposed INN: Treprostinil Other descriptive name: TREPROSTINIL SODIUM, UT-15 Trade Name: Remodulin® (treprostinil) 10 mg/ml solution for infusion INN or Proposed INN: Treprostinil Other descriptive name: TREPROSTINIL SODIUM, UT-15 Trade Name: Remodulin® (treprostinil) 1 mg/ml solution for infusion INN or Proposed INN: Treprostinil ... | United Therapeutics Corp. | NULL | Not Recruiting | Female: yes Male: yes | 50 | Germany | |||
| 5 | NCT01433328 (ClinicalTrials.gov) | January 201220120100 | 9/9/201120110909 | Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain | Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain | Pulmonary Arterial Hypertension | Drug: Lidocaine;Drug: Placebo | Jewish General Hospital | NULL | Terminated | 18 Years | 85 Years | All | 4 | Phase 4 | Canada |
| 6 | EUCTR2011-001312-59-GB (EUCTR) | 24/06/201120110624 | 15/04/201120110415 | A double-blinded, randomized, crossover clinical study to assess the efficacy of Qutenza (capsaicin 8% patches) for the reduction of site pain caused by continuous subcutaneous infusion of Remodulin (treprostinil sodium), in Pulmonary Arterial Hypertension Patients - Efficacy of capsaicin 8% patches in Pulmonary Arterial Hypertension A double-blinded, randomized, crossover clinical study to assess the efficacy of Qutenza (capsaicin ... | A double-blinded, randomized, crossover clinical study to assess the efficacy of Qutenza (capsaicin 8% patches) for the reduction of site pain caused by continuous subcutaneous infusion of Remodulin (treprostinil sodium), in Pulmonary Arterial Hypertension Patients - Efficacy of capsaicin 8% patches in Pulmonary Arterial Hypertension A double-blinded, randomized, crossover clinical study to assess the efficacy of Qutenza (capsaicin ... | Pulmonary arterial hypertension (PAH) is a rare life-threatening disease characterised by high blood pressure in the arteries to the lungs, rapidly evolving in a clinical syndrome of dyspnoea and fatigue and eventually leading to right ventricular failure and death. MedDRA version: 13.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders Pulmonary arterial hypertension (PAH) is a rare life-threatening disease characterised by high blood ... | Trade Name: Qutenza Product Name: Qutenza INN or Proposed INN: Capsaicin | Imperial College London | NULL | Not Recruiting | Female: yes Male: yes | 0 | United Kingdom | |||
| 7 | NCT01266265 (ClinicalTrials.gov) | December 201020101200 | 22/12/201020101222 | Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA A ... | A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial ... | Pulmonary Arterial Hypertension | Drug: inhaled prostacyclin;Drug: prostacyclin;Drug: subcutaneous and intravenous prostacyclin;Drug: oral ERA;Drug: oral PDE5 inhibitors Drug: inhaled prostacyclin;Drug: prostacyclin;Drug: subcutaneousand intravenous prostacyclin;Drug: o ... | United Therapeutics | NULL | Completed | N/A | N/A | All | 1333 | N/A | United States |
| 8 | NCT00705133 (ClinicalTrials.gov) | July 200820080700 | 23/6/200820080623 | Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension TreprostinilTherapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypert ... | Using Either Intravenous (IV) or Subcutaneous (SQ) Treprostinil to Treat Pulmonary Hypertension Related to Underlying Interstitial Lung Disease Using Either Intravenous (IV) or Subcutaneous(SQ) Treprostinilto Treat Pulmonary Hypertension Relate ... | Pulmonary Arterial Hypertension;Interstitial Lung Disease;Idiopathic Pulmonary Fibrosis | Drug: Treprostinil | Rajan Saggar | United Therapeutics | Completed | N/A | N/A | All | 15 | Phase 2 | United States |
| 9 | NCT00058929 (ClinicalTrials.gov) | October 200220021000 | 14/4/200320030414 | A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension | A Multicenter, Randomized, Parallel Placebo-Controlled Study of the Safety and Efficacy of Subcutaneous Remodulin® Therapy After Transition From Flolan® in Patients With Pulmonary Arterial Hypertension A Multicenter, Randomized, Parallel Placebo-Controlled Study of the Safety and Efficacy of Subcutane ... | Pulmonary Arterial Hypertension;Pulmonary Hypertension | Drug: treprostinil sodium | United Therapeutics | NULL | Completed | 18 Years | 75 Years | Both | 39 | Phase 4 | United States |